JAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: The data of the present study showed that Ruxolitinib, a JAK1/2 inhibitor, can attenuate the effect of hypoxia or HIF1α overexpression in mediating Crizotinib resistance in CML cells.